C
Carlos Cordon-Cardo
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 620
Citations - 91832
Carlos Cordon-Cardo is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 144, co-authored 589 publications receiving 84862 citations. Previous affiliations of Carlos Cordon-Cardo include The Rogosin Institute & Erasmus University Rotterdam.
Papers
More filters
Journal Article
Relation between human papillomavirus positivity and p16 expression in head and neck carcinomas--a tissue microarray study.
Frank König,Gisbert Krekeler,Johannes Franz Hönig,Carlos Cordon-Cardo,G. Fischer,Monika Korabiowska +5 more
TL;DR: A statistically significant relationship was demonstrated between HPV16, 18 presence and increased expression of p16 and this study demonstrates that it is possible to analyse p16 expression and HPV presence by tissue microarrays.
Journal ArticleDOI
Expression of Granulocyte-Macrophage Colony-Stimulating Factor Receptors in Human Prostate Cancer
Coralia I. Rivas,Juan Carlos Vera,Fernando Delgado-López,Mark L. Heaney,Victor H. Guaiquil,Rong H. Zhang,Howard I. Scher,Ilona I. Concha,Francisco Nualart,Carlos Cordon-Cardo,David W. Golde +10 more
TL;DR: The data show that the LNCaP cells express functional GM- CSF receptors and that prostatic carcinomas have prominent GM-CSF receptor expression, implying that both hyperplastic and neoplastic prostatic tissues may be responsive to GM-csF.
Journal ArticleDOI
Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice
Ernane D. Reis,Mercè Roqué,Hayes M. Dansky,John T. Fallon,Juan J. Badimon,Carlos Cordon-Cardo,Steven Shiff,Edward A. Fisher +7 more
TL;DR: Results demonstrate sulindac reduces neointimal formation in both normolipidemic and hyperlipidemic settings and raise the possibility that similar benefits may be obtained in patients undergoing angioplasty and related procedures.
Journal ArticleDOI
P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder
TL;DR: The data show that an increase in the proportion of cells expressing P-glycoprotein occurs after exposure to a combination chemotherapy program containing drugs known to select for P- glycoprotein expression in vitro.
Journal ArticleDOI
Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer.
Alison G. Barber,Mireia Castillo-Martin,Dennis M. Bonal,Benjamin A. Rybicki,Angela M. Christiano,Carlos Cordon-Cardo +5 more
TL;DR: It is reported for the first time that a low DSG2 expression phenotype is a useful prognostic biomarker of tumor aggressiveness and may serve as an aid in identifying patients with clinically significant prostate cancer.